Nikhil I Khushalani

26PUBLICATIONS
250CO-AUTHORS
Predictive and prognostic markersMolecular targetsTumour immunologyCancer therapy (excl. chemotherapy and radiation therapy)Engineering electromagnetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Jun 23, 2026
Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

|Apr 21, 2026
Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1.

|Feb 27, 2026
Survival Assessment by Central Review vs. Local Investigator in Metastatic Melanoma: A Systematic Review and Meta-Analysis.

Islam Eljilany, Eissa Jafari, Abdullah Alhumaid

|Jan 14, 2026
Neoadjuvant lenvatinib plus pembrolizumab in Merkel cell carcinoma: an investigator-initiated, open-label phase II trial.

Andrew S Brohl, Vernon K Sondak, Evan J Wuthrick

|Nov 04, 2025
RAS(ON) Multiselective Inhibition Drives Antitumor Immunity in Preclinical Models of NRAS-Mutant Melanoma.

Larissa Anastacio Da Costa Carvalho, Nataliya Tovbis Shifrin, Manali S Phadke

|Mar 06, 2025
Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases.

Sarah A Weiss, Dijana Djureinovic, Wei Wei

Pageof 5

Frequent Collaborators

10 joint publications

Zeynep Eroglu

8 joint publications

Vernon K Sondak

7 joint publications

Amod Sarnaik

7 joint publications

Jeffrey Weber